Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5
暂无分享,去创建一个
C. E. Parker | L. Deterding | C. Hager-Braun | J. Binley | N. Schülke | H. Katinger | John P. Moore | K. Tomer | C. Parker
[1] S. Zolla-Pazner,et al. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody , 1992, Journal of virology.
[2] G Himmler,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.
[3] T. Matthews,et al. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.
[4] A. Trkola,et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS , 1994, Journal of virology.
[5] D R Burton,et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.
[6] A. Trkola,et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.
[7] A. Trkola,et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.
[8] E. Emini,et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[9] S. Zolla-Pazner,et al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D , 1994, Journal of virology.
[10] Stephen C. Blacklow,et al. A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.
[11] A. Trkola,et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.
[12] Q. Sattentau,et al. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. , 1995, Virology.
[13] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[14] A. Trkola,et al. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5 , 1996, AIDS.
[15] C. Barbas,et al. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. , 1996, AIDS research and human retroviruses.
[16] A. Trkola,et al. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex , 1997, Journal of virology.
[17] S. Harrison,et al. Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.
[18] D. Burton. A vaccine for HIV type 1: the antibody perspective. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[19] D. Burton,et al. The antibody response in HIV-1 infection. , 1997, AIDS.
[20] C. Burrell,et al. Enhancement or inhibition of HIV‐1 replication by intracellular expression of sense or antisense RNA targeted at different intermediates of reverse transcription , 1997, AIDS.
[21] J. Bradac,et al. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.
[22] S. Rowland-Jones,et al. Role of cellular immunity in protection against HIV infection. , 1997, Advances in immunology.
[23] Dennis R. Burton,et al. Why do we not have an HIV vaccine and how can we make one? , 1998, Nature Medicine.
[24] N. Letvin. Progress in the development of an HIV-1 vaccine. , 1998, Science.
[25] Eric Hunter,et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.
[26] P. S. Kim,et al. HIV Entry and Its Inhibition , 1998, Cell.
[27] D. Baltimore,et al. HIV Vaccines—where are we going? , 1998, Nature Medicine.
[28] D. Montefiori,et al. Induction of immune responses to HIV‐1 by canarypox virus (ALVAC) HIV‐1 and gp120 SF‐2 recombinant vaccines in uninfected volunteers , 1998, AIDS.
[29] E. Hunter,et al. A Conserved Tryptophan-Rich Motif in the Membrane-Proximal Region of the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Is Important for Env-Mediated Fusion and Virus Infectivity , 1999, Journal of Virology.
[30] Q. Sattentau,et al. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. , 1999, AIDS.
[31] D. Montefiori,et al. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. , 1999, AIDS research and human retroviruses.
[32] J. Mascola,et al. Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.
[33] S. Zolla-Pazner,et al. Mass Spectrometric Characterization of a Discontinuous Epitope of the HIV Envelope Protein HIV-gp120 Recognized by the Human Monoclonal Antibody 1331A1 , 2000, The Journal of Immunology.
[34] Y. Xiao,et al. Induction of monoclonal antibody with predefined ELNKWA epitope specificity by epitope vaccine. , 2000, Hybridoma.
[35] Tahir A. Rizvi,et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.
[36] Ying-hua Chen,et al. Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine☆ , 2000, Peptides.
[37] Ying-hua Chen,et al. Immunogenicity of Neutralizing Epitopes on Multiple–Epitope Vaccines against HIV–1 , 2000, International Archives of Allergy and Immunology.
[38] Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1. , 2000, Immunobiology.
[39] J. Binley,et al. Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits , 2000, Journal of Virology.
[40] Lǔ,et al. Multiepitope Vaccines Intensively Increased Levels of Antibodies Recognizing Three Neutralizing Epitopes on Human Immunodeficiency Virus‐1 Envelope Protein , 2000, Scandinavian journal of immunology.
[41] S. Zolla-Pazner,et al. Recognition by Human Monoclonal Antibodies of Free and Complexed Peptides Representing the Prefusogenic and Fusogenic Forms of Human Immunodeficiency Virus Type 1 gp41 , 2000, Journal of Virology.
[42] Ying-hua Chen,et al. Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope ELDKWA and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines against HIV-1 , 2000, International Archives of Allergy and Immunology.
[43] K. Tomer,et al. Epitope mapping by a combination of epitope excision and MALDI-MS. , 2000, Methods in molecular biology.
[44] C Leclerc,et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. , 2000, Vaccine.
[45] A. Simon,et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.
[46] B. Moss,et al. Immunization with a Modified Vaccinia Virus Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol Primes for an Anamnestic Gag-Specific Cytotoxic T-Lymphocyte Response and Is Associated with Reduction of Viremia after SIV Challenge , 2000, Journal of Virology.
[47] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[48] Ying-hua Chen,et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody , 2000, Immunological investigations.
[49] A structure-based approach to a synthetic vaccine for HIV-1. , 2000, Biochemistry.
[50] Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1. , 2000, FEMS immunology and medical microbiology.
[51] J. Binley,et al. A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.
[52] K. Tomer,et al. A general strategy for epitope mapping by direct MALDI-TOF mass spectrometry using secondary antibodies and cross-linking. , 2001, Analytical chemistry.
[53] B. Moss,et al. Elicitation of High-Frequency Cytotoxic T-Lymphocyte Responses against both Dominant and Subdominant Simian-Human Immunodeficiency Virus Epitopes by DNA Vaccination of Rhesus Monkeys , 2001, Journal of Virology.
[54] C. Cheng‐Mayer,et al. Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.
[55] S. Rowland-Jones,et al. Cellular immune responses to HIV , 2001, Nature.
[56] Y. Xiao,et al. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41. , 2001, Immunology letters.
[57] James G. Herndon,et al. Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine , 2001, Science.
[58] Michael S. Kay,et al. Protein Design of an HIV-1 Entry Inhibitor , 2001, Science.
[59] R. Steinman,et al. Mature Dendritic Cells Infected with Canarypox Virus Elicit Strong Anti-Human Immunodeficiency Virus CD8+and CD4+ T-Cell Responses from Chronically Infected Individuals , 2001, Journal of Virology.
[60] G. Nabel. Challenges and opportunities for development of an AIDS vaccine , 2001, Nature.
[61] P. Earl,et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. , 2002, Vaccine.